Lenacapavir: An Overview’
Lenacapavir, Capsid-Inhibitor, HIV-1, Anti-Retroviral agent, SUNLENCA.
Lenacapavir was approved for medical use in European Union in August-2022, Lenacapavir is the first of a new class of drugs called "Capsid inhibitors to be FDA-approved for treating HIV/AIDS. Lenacapavir a new type of antiretroviral medication for adult patients living with Human Immunodeficiency Virus type-1(HIV-1), who’s HIV Infections cannot be successfully treated with other available treatments due to resistance, intolerance considerations. Lenacapavir works by blocking the HIV-1 virus' protein shell (the Capsid) .Lenacapvir, in combination with other antiretroviral(s), is indicated for the treatment of multidrug-resistant human immunodeficiency virus type-1 (HIV-1)-Infection. Lenacapvir first formulation Oral Tablets and Subcutaneous injection-form at trade Name-(Sunlenac), Lenacapavir -is achieved in HIV RNA suppression .Lenacapvir is a long- acting, potent inhibitor of the HIV Capsid protein. Lenacapavir binds directly to HIV-capsid in a pocket between capsid protein subunits in hexamers.Treatement of emergent resistance to lenacapvir has been reported in the phase 2/3 CAPELLA trail evaluating Lenacapvir for HIV treatment. Combination antiretroviral therapy-suppression HIV-1 replication and increase CD 4+ cell counts.
Article Details
Unique Paper ID: 158616

Publication Volume & Issue: Volume 9, Issue 10

Page(s): 251 - 265
Article Preview & Download

Share This Article

Join our RMS

Conference Alert

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024

Last Date: 15th March 2024

Call For Paper

Volume 10 Issue 10

Last Date for paper submitting for March Issue is 25 June 2024

About Us

IJIRT.org enables door in research by providing high quality research articles in open access market.

Send us any query related to your research on editor@ijirt.org

Social Media

Google Verified Reviews